Page last updated: 2024-11-04

temozolomide and Icterus

temozolomide has been researched along with Icterus in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma."7.80Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. ( Adeyi, O; Fung, S; Mason, M; Millar, BA, 2014)
"Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma."3.80Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. ( Adeyi, O; Fung, S; Mason, M; Millar, BA, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pellini Ferreira, B1
Vasquez, J1
Carilli, A1
Mason, M1
Adeyi, O1
Fung, S1
Millar, BA1

Other Studies

2 other studies available for temozolomide and Icterus

ArticleYear
Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
    The American journal of the medical sciences, 2017, Volume: 353, Issue:6

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Biopsy; Capecitabine; Car

2017
Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
    BMJ case reports, 2014, Nov-28, Volume: 2014

    Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Chemical and Drug Induced Liver

2014